Month: 2025-01

SINGAPORE, Jan 25, 2025 - (ACN Newswire via SeaPRwire.com) - Momomi®, the internationally acclaimed home brand with over 20 million sales worldwide, is proud to introduce the Momomi® Mat to the Singapore market. Designed to cater to all ages, this revolutionary mat seamlessly blends innovation, elegance, and practicality to enhance family living.The Momomi® Mat is renowned for its softness, durability, and easy maintenance, making it an ideal choice for busy households. Featuring the exclusive PuffySponge™ formula, it is 100% waterproof, quick-to-dry, and resistant to pilling or shedding, making it pet-friendly and perfect for all seasons. Its 30mm thickness offers superior comfort for everything from playtime with kids to cozy family moments.Beyond its functional design, the Momomi® Mat adds a touch of sophistication to any space, whether in living rooms, bedrooms, or baby play areas. Winner of the Best Playmat Award and the International Innovative Design Award, the mat has set a new standard in home furnishings.Momomi® is also committed to ethical production, collaborating with female artisans to craft high-quality products while providing them with sustainable income opportunities. This dedication to artistry and integrity shines through in every mat, which merges traditional craftsmanship with modern innovation.To cater to unique spaces, Momomi® offers customizable options, allowing customers to create mats perfectly tailored to their needs. Maintenance is effortless-spills wipe clean in seconds, and the mat retains its shape and beauty over time.The Momomi® Mat is now available in Singapore through the official website, momomi.world.Contact InformationJosephine C.Marketing Managercontact@momomi.worldSOURCE: Momomi® Copyright 2025 ACN Newswire via SeaPRwire.com.

SHENZHEN, CHINA, Jan 24, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 24 January 2025, the Group through subsidiaries of the Company entered into a Collaboration Agreement with Hunan Mabgeek Biotechnology Co., Ltd. (“Mabgeek Biotechnology”) and its subsidiary for Class 1 innovative drug anti-IL-4Rα humanized monoclonal antibody injection MG-K10 (“MG-K10” or the “Product”). The Group has obtained the co-development right as specifically agreed upon in the Agreement and exclusive commercialization right to the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and Singapore (the “Territory”); Mabgeek Biotechnology will support the commercialization activities and is responsible for the sale and supply of the Product. The collaboration term is perpetual.IL-4Rα is considered a key target for the treatment of type 2 inflammatory diseases, such as atopic dermatitis (AD), asthma, prurigo nodularis, etc. Anti-IL-4Rα monoclonal antibodies are among the best-selling biologics in this field. MG-K10 is an innovative long-acting anti-IL-4Rα humanized monoclonal antibody that simultaneously blocks the signaling of key type 2 inflammatory cytokines IL-4 and IL-13. Following Fc mutation, MG-K10 allows long dosing interval owing to its prolonged half-life, and it is expected to be the first long-acting anti-IL-4Rα monoclonal antibody marketed in China. Currently marketed anti-IL-4Rα drugs require dosing every two weeks, whereas MG-K10 only requires dosing every four weeks, demonstrating good efficacy and safety. MG-K10 has the potential to be the Best-in-Class (BIC).This collaboration marks another significant milestone for Dermavon (formerly known as CMS Skinhealth)’s layout in the dermatology field. MG-K10 will enrich the global differentiated innovative pipeline of Dermavon, and will strongly synergize with the existing product portfolio, such as marketed innovative drug ILUMETRI (tildrakizumab injection), marketed exclusive drug Hirudoid (mucopolysaccharide polysulfate cream) and dermatology-grade skincare products of Heling soothing product series (developed for AD patients), and innovative pipeline drugs ruxolitinib cream (for the topical treatment of mild to moderate AD and non-segmental vitiligo) and povorcitinib (for the treatment of non-segmental vitiligo, hidradenitis suppurativa, prurigo nodularis and chronic spontaneous urticaria), etc. Leveraging its proven clinical development and commercialization capabilities, the Group will fully cooperate with Mabgeek Biotechnology to promote the approval of MG-K10 in China, bringing a new treatment option with lower dosing frequency, good efficacy and safety to patients with type 2 inflammatory diseases in China.More information about MG-K10MG-K10 is a Class 1 innovative drug anti-IL-4Rα humanized monoclonal antibody injection that used for the treatment of type 2 inflammatory diseases, including AD, asthma, prurigo nodularis, allergic rhinitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, chronic obstructive pulmonary disease and so on. It holds substance patents in specific countries/regions within the Territory.MG-K10 has entered Phase III clinical trials in China for AD, asthma, and prurigo nodularis. In the completed Phase II clinical trials for adult moderate-to-severe AD and moderate-to-severe asthma, MG-K10 has demonstrated good efficacy and safety[1-2]. Additionally, MG-K10 has obtained IND approval for eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis in China.According to Frost & Sullivan, the global market for treatments targeting IL-4Rα is expected to reach US$28.7 billion by 2030, with a compound annual growth rate (CAGR) of 21.8% from 2020 to 2030. In China, the market is projected to reach US$4.08 billion by 2030, with a CAGR of 76.8% from 2020 to 2030.About AD indicationMG-K10’s first indication, AD, is a chronic inflammatory skin condition characterized by severe itching. It is the most burdensome non-fatal skin disease globally, with at least 230 million people affected worldwide[3]. AD is also a prevalent and high-burden chronic disease in China, with the prevalence showing an upward trend[3]. According to the Global Burden of Disease Study 2019, the number of AD patients in China increased by 25.65% from 1990 to 2019[3]. It is estimated that there are approximately 36.09 million AD patients in China[3], with approximately 9.625 million suffering from moderate-to-severe AD[4].Current treatment options for AD primarily include topical and systemic treatments. For moderate-to-severe AD, topical medications are often insufficient to achieve disease control, necessitating the initiation of systemic treatments. However, due to the limitations in efficacy and safety of traditional systemic therapies for AD, moderate-to-severe AD patients often experience delays in systemic treatment initiation, poor compliance, and suboptimal disease control, leaving a significant unmet need in clinical practice[3]. MG-K10, with its extended dosing interval of once every four weeks, is expected to improve patient adherence and provide a new, effective, and safe systemic treatment option for patients with moderate-to-severe AD.About Mabgeek BiotechnologyMabgeek Biotechnology was founded in 2016 and has always adhered to the research and development concept of “innovation, efficiency and safety”, focusing on the fields of allergic inflammatory diseases and autoimmune diseases. Mabgeek Biotechnology is equipped with a research and development team composed of top industry experts. With excellent research capabilities and deep industry experience, Mabgeek Biotechnology uses its unique TEADA high-throughput antibody screening platform to develop innovative antibody drugs with high biological activity, excellent druggability, and differentiation. Mabgeek Biotechnology is committed to providing safer, more effective and more convenient treatment solutions for patients worldwide. For more information about Mabgeek Biotechnology and its products, please visit: https://www.mabge.com/.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a “bridgehead” for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.Reference:1. The data of the product’s Phase II clinical trial for AD indication as disclosed by Mabgeek: https://www.mabge.com/en/index.php?c=show&id=232. The interim data of the product’s Phase II clinical trial for asthma indication as disclosed by Mabgeek: https://www.mabge.com/index.php?c=show&id=183. Chinese Society of Dermatology, China Dermatologist Association. Clinical pathway for the diagnosis and treatment of moderate to severe atopic dermatitis in China (2023): an expert consensus[J]. Chinese Journal of Dermatology, 2023, 56(11): 1000-1007. DOI: 10.35541/cjd.20230247.4. Mao, Dandan et al. Prevalence and risk factors of atopic dermatitis in Chinese adults: a nationwide population-based cross-sectional study. Chinese medical journal vol. 136,5 604-606. 5 Mar. 2023, DOI:10.1097/CM9.0000000000002560CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2025 ACN Newswire via SeaPRwire.com.

SINGAPORE, Jan 24, 2025 - (ACN Newswire via SeaPRwire.com) - Tired of random DMs, awkward intros, or shallow connections? Viberse, the social app for connecting with people through sharing glimpses of life, introduces Tango—a fun, daily mission designed to help users break the ice and make new friends worldwide.The new Tango tab features Bingo Tango, a fresh twist on bingo, where users share their daily lives through photos or videos to unlock the ability to chat directly via messaging.https://youtube.com/shorts/sHaJ4SS2U5w?si=JHL6alkDofT-hxKnThink of Bingo Tango as bingo reimagined; instead of numbers on cards, it connects people through shared moments. Whether it’s posting your “(CoffeeRun) OTD” or reminiscing with “BackTo (FirstConcert),” Tango turns everyday stories into conversations and friendships.According to Viberse, the name “Bingo Tango” captures the collaboration and back-and-forth rhythm needed for two people to connect. Like a dance, partners take turns sharing moments, creating a natural flow. Once a bingo is scored—completing the mission—the two users unlock chat to connect deeper.A new, fun way to socializeTango isn’t just a feature—it’s a new way to socialize. By teaming up to share on the same topics, users create mutual vibes and meaningful bonds. Completing 6 posts across 3 matching topics finishes the Bingo Tango mission and unlocks a direct chat.Bingo Tango, a daily mission to befriend people. COURTESY OF VIBERSEAt its core, Tango is about building connections through shared content and collaboration. Unlike random DMS, every connection on Viberse starts with teamwork and mutual vibes, making each connection meaningful and genuine.“You never know who you’ll pair up with, what topics they’ll choose, or the stories they’ll share,” says the Viberse team. “This unpredictability, combined with authentic exchanges, makes socializing on Viberse exciting, genuine, and personal.”Tango redefines socializing by turning everyday stories into steps toward new friendships. Purposeful, playful, and deeply personal, it’s perfect for anyone ready to connect beyond the ordinary.About ViberseFounded in 2024 in Singapore, Viberse Technology is creating a platform where users can explore the extraordinary within everyday life, share their experiences, and connect meaningfully with others. Viberse offers a more authentic way to socialize in the digital age.Media ContactChristine Linchristine.lin@viberse.com Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Jan 24, 2025 - (ACN Newswire via SeaPRwire.com) - Celebrating its 2nd anniversary, Artelli proudly stands as Macau's pioneering multi-dimensional art space, establishing itself as a brand in the art world with a mission to "Anchored in Asia, Connecting the World Through Art". This year's anniversary marks a significant milestone, with Artelli honored by two prestigious awards: the 2024 Asia-Pacific Stevie® Awards for Excellence in Innovation (Bronze) and the Marketing Events Awards Hong Kong 2024 for Best Event in Arts, Leisure and Entertainment (Silver). These accolades not only affirm Artelli's role as a driving force in the arts but also highlight the brand's commitment to opening new perspectives in cultural exchange between Asia and the international community.Bridging borders and art forms with 20+ multicultural art projects across four distinct locationsSince its founding in 2022, Artelli has been passionately dedicated to connecting Asia's art enthusiasts with the global art community. Over the past two years, Artelli has curated more than 20 debut exhibitions across Greater China, showcasing a spirited tapestry of contemporary art, pop art, iconic cross-disciplinary collaborations, and cutting-edge Web 3.0 digital art. These exhibitions have drawn over 6 million visitors and received extensive international media coverage with more than 2,000 mentions in articles. Embraced enthusiastically by the art community, these exhibitions have also paved the way for innovative integration of "Culture + Tourism + Art", marking the unique creative collaboration.In addition, Artelli fosters exclusive collaborations with artists to create original and irresistible art experiences. Artists are invited to Macau early in the planning stages of exhibitions, allowing them to immerse themselves in the city's distinctive cultural landscape. Drawing inspiration from Macau's multicultural heritage, these artists infuse their work with a strong sense of place and purpose, contributing pieces that capture an assertive allure and resonate powerfully with both local and international audiences.Japanese artist Yuya Hashizume explored Macau's vibrant culture before his "eyewater+" debut exhibition, drawing inspiration from the city's signature colors, vermilion red, ink green, and yellow. His Macau-exclusive works were showcased at Artelli.In the convergence of "Art" and "Intelligence", the name Artelli was born. It embodies the brand's commitment to pioneering innovation in art and technology. As a forward-thinking, next-generation art platform, Artelli collaborates with artists to create unique, original content. From initial concept to final presentation, every part of the process is a prodigious endeavor, including creation, curation, exhibition design, artist events, and merchandise. Behind each detail is the work of the Macau-based curatorial team, reflecting the dedication and peerless attention in delivering a fully immersive 360° experience. Artelli is also committed to utilizing diverse resources and actively expanding robust cross-sector collaborations. Through a distinctive curatorial approach that seamlessly integrates art, technology, and the commercial sector, Artelli deepens the impact and reach of the arts, making each exhibition a meaningful testament to the value and potential of art in our modern society.Core Curatorial Team of ArtelliAn immersive art journey curated in three languages, guided by art ambassadorsArtelli's flagship store is located in the heart of Macau's Cotai district, within the spacious confines of The Showroom at City of Dreams. This dynamic, multi-functional space spans 600 square meters across two and a half floors, envisioned by the renowned French interior design agency Malherbe Paris. Tasked with materializing Artelli's vision, the interior is defined as a true artistic canvas, reflecting the fluidity of natural landscapes to complement all forms of art. With a pure white palette, the layout features an open, interwoven structure that harmoniously reveals distinct zones. Visitors journey along the immersive viewing path, as if they are walking through a modern art sanctuary, watching each artwork unfold dynamically with shifts in time and perspective. To elevate art experience, Artelli also offers guided tours in three languages, instilling visitors with the stories behind the artworks and insights into the creative visions of each artist, reimagining cross-cultural connections in its spirits of innovation.Artelli’s vision for the future sees abundance opportunities for innovation in the sustainable development of artFor over 700 days, Artelli has driven curatorial practices with original content, presenting international art projects fueled by the team's passion and expertise. The art space has emerged as a rising star in the global art scene.Looking ahead, Artelli is committed to pursue innovations in art, curating groundbreaking global art projects and empowering culture through transformative art education by hosting masterclasses, academic forums, and workshops to broaden public access to art. Through comprehensive, one-stop curation and project management, Artelli strives to establish itself as an international landmark for art and culture that connects global and local art communities. Believing in art as a universal language, Artelli sparks conversations that inspire and connect across cultures.In parallel, Artelli is dedicated to nurturing artistic talent in creative processes such as curation, visual arts, and art consultancy, bringing fresh energy to the art ecosystem in Macau and across Asia.As a pioneering art label in Asia, Artelli looks forward to continuing its journey of connecting diverse cultures around the globe through artistic initiatives, transforming art as a universal language that transcends regions and cultures. Artelli aims to bring lasting momentum to the arts and culture scene in Macau and Asia, with a long-term vision of driving sustainable development in the art industry.Featured Highlight Projects2024 | City of Dreams and Artelli Jointly Presented The "Crowning Journey of Jean-Michel Basquiat"Artelli and City of Dreams proudly presented Legendary artist Jean-Michel Basquiat's "Crowning Journey" across four major areas at City of Dreams Macau: The Main Portal, Southwest Entrance (outdoor area), The Showroom, and Artelli – The Pioneering Multi-dimensional Art Space. Large-scale installations, multimedia, immersive and interactive multi-dimensional experiences took the audience on an unprecedented journey, inviting them to explore the thoughts and ideas of Jean-Michel Basquiat.For the event, a series of merchandise that references Basquiat's powerful expressionism was released, including the special edition of Mahjong Set, Art Puzzle, and Postcard set. These products creatively integrate the artist's iconic symbols and creative spirit into everyday life.2024 | Internationally renowned Chinese artist Zhuang Hong-Yi's First solo exhibition in Macau "Shades of Blossoms"In this exhibition, Zhuang Hong-Yi presented his latest 'Flowerbed Series', using delicate Chinese rice paper and thick acrylic pigments of the Western style, to create visually rich and three-dimensional artworks. Zhuang's renowned and highly collectible "Flowerbed Colorchange" stands as a distinctive hallmark of his creations. When viewed from left to right, the artwork appears to change color, and the folded rice paper makes a cohesive piece when experienced up close, revealing a harmonious tapestry of seamlessly blended petal textures. The art space vibrated with the colorful floral elements that reveal a mirror of a flower sea, allowing each viewer to experience an enchanting and immersive scenery change with every step they take.2024 | Renowned Japanese Photography Master Nobuyoshi Araki’s "Paradise", A Collaborative Tribute Between Hong Kong and MacauCelebrating the 84th birthday of the renowned Japanese photography master Nobuyoshi Araki in May, Artelli, presented the "Paradise" showcased in collaboration with venues in Hong Kong and Macau, features over 200 iconic works spanning Araki's four-decade career, paying tribute to him in various ways. "Paradise" Hong Kong POP-UP takes place at CEMENT, the modular creative and community-driven space of K11 MUSEA, and Macau Exhibition located at Artelli with "Darkroom" to offer glimpse into Araki's photographic desires. At the time, highly collectible artist-signed instant photography works in deluxe editions were simultaneously available for purchase in Hong Kong and Macau.2024 | "Viral Code? – A Discussion on Art and the Masses" Zhao Xiaoli and Wu Xixia Dual ExhibitionSupported by the Macau Cultural Development Fund in 2024, the exhibition invited the internationally renowned artist and first Chinese female curator, Ms. Victoria Lu, as its academic advisor. Together with the two female artists, Zhao Xiaoli and Wu Xixia, they presented a journey of multiple reflections on art, audience engagement, and the identity of female creators. Through the themes explored in their works and their unique artistic perspectives, they conveyed positive messages of diversity and the multifaceted development of the art industry. Not only showcased art creations during the opening ceremony, Zhao Xiaoli and Wu Xixia also collaborated with Ms. Victoria Lu in hosting an art symposium and a fan signing session at Artelli. Together, they engaged the public in discussions about the stories and thoughts behind their creative processes.2024 | New York Artist Adam Handler's Largest Solo Exhibition in Asia "Always near you...Always"New York artist Adam Handler, captivated for his distinctive Kawaii Faux Naïf style, held his largest solo exhibition in Asia at Artelli. Over 100 international collectors and art enthusiasts attended the opening ceremony. The exhibition, themed "Love Heals", showcased Adam Handler's new works and debut creations, including the Ghost Series, the UFO Abduction Series, and the Battle Ground Series.2023 | Mr Doodle First Exhibition in MacaoArtelli, in its capacity as a co-organizer and curator, has presented the "Mr Doodle First Exhibition in Macao" with Melco Resorts & Entertainment. Mr Doodle’s meticulously created artworks could be seen throughout City of Dreams and Artelli, including the iconic public art building "Doodle Showroom" on the Cotai Strip, which reinvented the look of The Showroom with its sleek lines and unique patterns; "Doodle Hall" was a breathtaking immersive exhibition at the main entrance of City of Dreams while "Doodle Love Wall" was set as a large-scale public interactive art installation that launched on China's Valentine's Day; "Doodle Cube" launched as a multimedia art installation at the Morpheus Hotel that blended a distinctive style of graffiti with a free-flowing architectural design. Additionally, the exhibition featured the "Mr Doodle Afternoon Tea Experience" and marked the global debut of the limited-edition "Disney Art Collection by Mr Doodle" at Artelli.2023 | Japan's Legendary Artist Takeru Amano "Attack of Clone Venus" Hong Kong & Macau DebutThis exhibition marked Takeru Amano's first showcase that features 450 NFT digital and physical collectibles, along with sculptures and giant art installations. "Attack of Clone Venus" was inspired by over 1,000 items from Takeru Amano's daily life. The collection showed striking contrasts through its simplicity, minimalistic design, vibrant colors, and saturated hues. Those who purchased the limited art book are entitled to receive a corresponding NFT digital collectible. The art book is a valuable addition and a must-have item for collectors.Hi-res images for download:https://drive.google.com/drive/folders/1mH3r_czDW5qNzyQGc1AtOdGx5hvqHzNJ?usp=sharingAbout ArtelliArtelli is the pioneering multi-dimensional space for contemporary art, lifestyle aesthetics, digital and techno art, art communities, and brand collaborations. The space stands as a new and unprecedented international landmark for art and culture. Artelli will ultimately join forces with over a hundred internationally renowned artists and brand designers to co-create exclusive art projects and debut collections. With a dedicated focus on Web 3.0 digital art and metaverse, Artelli pioneers the exploration of new artistic dimensions. Guided by a strong commitment to become a multi-dimensional art space that fosters collaborations within the art and culture communities, Artelli's visionary path unfolds through the fusion of art, technology, and the dynamic commercial sector.Media Contacts: Marketing | marketing.mcin@forward-fashion.com | (853) 2871 8921 Copyright 2025 ACN Newswire via SeaPRwire.com.

美國，帕薩迪納, 2025年1月24日 - (亞太商訊 via SeaPRwire.com) - The Now Corporation（OTC PINK:NWPN）欣然宣布，其全資子公司綠雨太陽能公司（Green Rain Solar Inc.）正準備在美國西南地區建立重要的市場佈局，重點關注新墨西哥州與亞利桑那州的市場。該公司計畫與渠道合作夥伴合作，推動太陽能電動車（EV）充電站的普及，這是其致力於提供創新和可持續能源解決方案的關鍵步之一。為迎接此次拓展，綠雨太陽能公司已在亞利桑那州和新墨西哥州完成州務卿的註冊。該公司的長期願景是將太陽能集成到電動車基礎設施中，同時解決該地區高成本城市區域的能源需求。為進一步推進其增長戰略，綠雨太陽能公司將其西海岸地區辦公室遷至新墨西哥州。此舉反映出公司對該州廣闊的太陽能潛力及快速增長的太陽能面板安裝採用率的信心。此外，相較於加州，新墨西哥州的有利稅收政策將有助於降低營運成本，並創造投資社區太陽能項目的機會。「新墨西哥州與亞利桑那州為我們提供了一個獨特的機會，來拓展我們對城市太陽能與電網集成的願景。」現代公司首席執行官阿爾弗雷多·帕帕達基斯（Alfredo Papadakis）表示。「我們的目標是與具有前瞻思維的組織和社區合作，建立清潔、可靠的能源解決方案，包括太陽能整合的電動車充電網絡。」此次進軍西南地區符合綠雨太陽能公司更廣泛的使命，即成為可再生能源領域的領導者，為城市和鄉村市場提供可持續且可擴展的解決方案。關於 The Now Corporation The Now Corporation（OTC: NWPN）致力於通過其子公司 Green Rain Solar Inc. 推動清潔能源解決方案。Green Rain Solar 專注於都市屋頂太陽能安裝和電網連接電力解決方案，目標市場為高能源成本區域。通過結合最先進的太陽能與電池技術，The Now Corporation 致力於推動可再生能源領域的創新與可持續發展。關於 Green Rain Solar Inc.Green Rain Solar Inc.，The Now Corporation（OTC: NWPN）的全資子公司，是一家專注於都市太陽能與電網整合的太陽能公用事業公司。該公司開發創新的屋頂太陽能專案，將陽光轉化為電網連接電力，推動高成本都市區域的可持續能源解決方案。法律聲明：關於前瞻性陳述本新聞稿包含根據《1933年證券法》第27A條和《1934年證券交易法》第21E條的定義所述的前瞻性信息，並受這些條款所創設的安全港保護。本資料中包含有關預期未來事件和/或財務結果的陳述，這些陳述具有前瞻性性質，並可能面臨風險和不確定性。這些風險包括本新聞稿中所述的業務可能因不可預見的技術、安裝、許可或其他挑戰而未能完成。此類前瞻性陳述涉及風險、不確定性和其他因素，可能導致 The Now Corporation 的實際結果、表現或成就與本文所表達的內容有重大差異。除非根據美國聯邦證券法規定，The Now Corporation 不承擔因新信息、未來事件或其他原因公開更新任何前瞻性陳述的義務。如有媒體詢問，請聯絡：Michael CiminoMichael@pubcopr.com資料來源: The Now Corp. Copyright 2025 亞太商訊 via SeaPRwire.com.